乙醛脱氢酶与消化系统肿瘤:一种潜在的精准医疗策略*

doi:10.3969/j.issn.1672-5069.2025.01.004

Abstract

Zhou Jia, Zhou Jinyuan, Zhang Feiyu, et al. Acetaldehyde dehydrogenase in digestive system tumors: a potential precision target for medical strategy[J]. Journal of Practical Hepatology, 2025, 28(1): 13-16.

References

[1] Wang W, Wang C, Xu H, et al. Aldehyde dehydrogenase, liver disease and cancer. Int J Biol Sci, 2020, 16(6):921-934.
[2] O'Grady I, Anderson A, O'Sullivan J. The interplay of the oral microbiome and alcohol consumption in oral squamous cell carcinomas. Oral Oncol, 2020, 110: 105011.
[3] Birkova A, Hubkova B, Cizmarova B, et al. Currentview on the mechanisms of alcohol-mediated toxicity. Int J Mol Sci, 2021, 22(18):9686.
[4] Bray FA-O, Laversanne M, Sung HA-O, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3):229-263.
[5] Ng CS, Ong XJ, Au M, et al. ALDH2 polymorphism, alcohol intake and the attributable burden of cancer in East Asia: systematic review, meta-analysis, and modeling study. Ann Epidemiol, 2023, 85:113-120.e120.
[6] Koyanagi YA-O, Nakatochi MA-O, Namba SA-O, et al. Genetic architecture of alcohol consumption identified by a genotype-stratified GWAS and impact on esophageal cancer risk in Japanese people. Sci Adv, 2024, 10(4):eade2780.
[7] Flashner S, Shimonosono M, Tomita Y, et al. ALDH2 dysfunction and alcohol cooperate in cancer stem cell enrichment. Carcinogenesis, 2024, 45(1-2):95-106.
[8] Moody S, Senkin S, Islam SMA, et al. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat Genet, 2021, 53(11): 1553-1563.
[9] Wang W, He S, Zhang R, et al. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin. Biomed Pharmacother, 2020, 125:109940.
[10] Laszkowska M, Rodriguez S, Kim J, et al. Heavyalcohol use is associated with gastric cancer: Analysis of the National Health and Nutrition Examination Survey From 1999 to 2010. Am J Gastroenterol, 2021, 116(5):1083-1086.
[11] Suzuki A, Katoh H, Komura D, et al. Defined lifestyle and germline factors predispose Asian populations to gastric cancer. Sci Adv, 2020, 6(19):eaav9778.
[12] Kawakami R, Mashima T, Kawata N, et al. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Sci, 2020, 111(3):962-973.
[13] Cai Y, Zeng R, Peng J, et al. The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer. Aging (Albany NY), 2022, 14(17):7038-7051.
[14] Zhang Z, Chen Y, Zhuo Q, et al. ALDH2 gene rs671 G ＞ a polymorphism and the risk of colorectal cancer: A hospital-based study. J Clin Lab Anal, 2022, 36(12):e24789.
[15] Wang Y, Popovic Z, Charkoftaki G, et al. Multi-omics profiling reveals cellular pathways and functions regulated by ALDH1B1 in colon cancer cells. Chem Biol Interact, 2023, 384:110714.
[16] Kang X, Jadhav S, Annaji M, et al. Advancingcancer therapy with copper/disulfiram nanomedicines and drug delivery systems. Pharmaceutics, 2023, 15(6):1567.
[17] Wei PL, Prince GMSH, Batzorig U, et al. ALDH2 promotes cancer stemness and metastasis in colorectal cancer through activating β-catenin signaling. J Cell Biochem, 2023, 124(6):907-920.
[18] Zhang H, Xia Y, Wang F, et al. Aldehydedehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression. Adv Sci (Weinh), 2021, 8(10):2003404.
[19] Sun Y, Wang Q, Zhang Y, et al. Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p. J Hepatol, 2020, 73(3): 603-615.
[20] Chang YS, Tu SJ, Chen HD, et al. Integrated genomic analyses of hepatocellular carcinoma. Hepatol Int, 2023, 17(1):97-111.
[21] Xia P, Liu DH, Wang D, et al. SLC3A2, as an indirect target gene of ALDH2, exacerbates alcohol-associated liver cancer via the sphingolipid biosynthesis pathway. Free Radic Biol Med, 2023, 206:125-133.
[22] Liu ZY, Lin XH, Guo HY, et al. Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma. Int J Biol Sci, 2024, 20(7):2763-2778.
[23] Yu P, Cao S, Yang S-M, et al. RALDH1inhibition shows immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Immunol Res, 2024, 12(2):180-194.
[24] Pommergaard HC, Rasmussen A, Hillingso J, et al. Aldehyde dehydrogenase expression may be a prognostic biomarker and associated with liver cirrhosis in patients resected for hepatocellular carcinoma. Surg Oncol, 2022, 40:101677.
[25] Sun J, Ding J, Shen Q, et al. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma. J Hepatol, 2022,78(3):627–642.
[26] Shan YS, Chen LT, Wu CH, et al. No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol. Sci Rep, 2021, 11(1):14567.
[27] Lee JS, Lee H, Woo SM, et al. Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. Theranostics, 2021, 11(7):3472-3488.
[28] Nimmakayala RK, Leon F, Rachagani S, et al. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Oncogene, 2020, 40(1):215-231.
[29] Nie S, Qian X, Shi M, et al. ALDH1A3accelerates pancreatic cancer metastasis by promoting glucose metabolism. Front Oncol, 2020, 10:915.
[30] Tan M, Meng J, Sun X, et al. EPS8 supports pancreatic cancer growth by inhibiting BMI1 mediated proteasomal degradation of ALDH7A1. Exp Cell Res, 2021, 407(1):112782.

Acetaldehyde dehydrogenase in digestive system tumors: a potential precision target for medical strategy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zheng Hao, Zhang Shugeng, Wang Jiabei, et al. Therapeutic strategies for patients with recurrent hepatocellular carcinoma after liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 804-807.
[2]	Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.
[3]	Wang Lingling, Yao Min, Yao Dengfu. Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 953-956.
[4]	Li Xiaobin, Liu Bowen, Hu shiping. Lipid metabolic reprogramming in the carcinogenesis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 957-960.
[5]	Zhang Weiping, Ge Hongyan. Pyroptosis and its roles in hepatocellular carcinogenesis [J]. Journal of Practical Hepatology, 2024, 27(5): 797-800.
[6]	Zhang Yingying, Wei Kele, Ding He, et al. Risk factors of spontaneous bacterial peritonitis and peripheral blood mononuclear cell CD36/mTORC1 signal pathway expression in patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(1): 80-83.
[7]	Fang Huijing, Zhu Chuanlong, Zhang Lili. Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 449-452.
[8]	Li Qinghan, Zhen Zuojun, He Yintao. Short-term efficacy of TACE, RFA, anti-PD-1 antibody and apatinib combination in the treatment of patients with postoperative recurrent hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(5): 714-717.
[9]	Wang Xiaoyan, Zhong Xueyu, Wu Chunyan. Impact of saxagliptin on AMPK/mTOR-TFEB autophagy signaling pathway in rats with non-alcoholic fatty liver disease and concomitant type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(4): 476-479.
[10]	Wang Yuanping, Zheng Lulu, Zhang Guangliang. A pilot study of MR and 4DCT images in the delineation of target area in patients with primary liver cancer undergoing first radiotherapy [J]. Journal of Practical Hepatology, 2022, 25(4): 567-570.
[11]	Wang Qixia, Ma Xiong. Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 457-459.
[12]	Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.
[13]	Liu Ruiqing,Yuan Xiaopeng. Mechanism of hypoxia inducible factor-1α involving in liver fibrosis [J]. Journal of Practical Hepatology, 2021, 24(1): 145-148.
[14]	Li Ying, Huang Haiqing, Xue Fushan, et al. Clinical observation of remifentanil combined with propofol target-controlled infusion anesthesia in patients with primary liver cancer underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2020, 23(2): 272-275.
[15]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.